Current Issue

Clinical/translational cancer immunotherapy

• Original research: Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects (11 August, 2020)

  Julia Delahousse, Charles Skarbek, Mélanie Desbois, Jean-Luc Perfettini, Nathalie Chaput, Angelo Paci
• Original research: CD163⁺ cytokine-producing cDC2 stimulate intratumoral type 1 T cell responses in HPV16-induced oropharyngeal cancer (7 August, 2020)

  Saskia J Santegoets, Chantal L Duurland, Ekaterina J Jordanova, Vanessa J van Ham, Ilina Ehsan, Nikki M Loof, Vipin Narang, Charles A Dutertre, Florent Ginhoux, Sylvia L van Egmond, Marij J P Welters, Sjoerd H van der Burg
• Original research: Genetic associations of T cell cancer immune response-related genes with T cell phenotypes and clinical outcomes of early-stage lung cancer (6 August, 2020)

  Qinchaung Wang, Jianchun Gu, Linbo Wang, David W Chang, Yuanqing Ye, Maosheng Huang, Jack A Roth, Xifeng Wu
• Original research: Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8⁺ T cells (5 August, 2020)

  Sandeep Kumar, Sunil Kumar Singh, Navin Viswakarma, Gautam Sondarva, Rakesh Sathish Nair, Periannan Sethupathi, Matthew Dorman, Subhash C Sinha, Kent Hoskins, Gregory Thatcher, Basabi Rana, Ajay Rana
• Original research: Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up (4 August, 2020)

  Joost H van den Berg, Bianca Heemskerk, Nienke van Rooij, Raquel Gomez-Eerland, Samira Michels, Maaike van Zon, Renate de Boer, Noor A M Bakker, Annelies Jorritsma-Smit, Marit M van Buuren, Pia Kvistborg, Hergen Spits, Remko Schotte, Henk Mallo, Matthias Karger, Joris A van der Hage, Michel W J M Wouters, Loes M Pronk, Marnix H Geukes Foppen, Christian U Blank, Jos H Beijnen, Bastiaan Nuijen, Ton N Schumacher, John B A G Haanen
• Original research: An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors (4 August, 2020)

  Kirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, Ben Wang, Shu Yi Shen, Ilias Ettayebi, Charles A Ishak, Philippe L Bedard, Albiruni Abdul Razak, Aaron R Hansen, Anna Spreafico, Dave Cescon, Marcus O Butler, Amit M Oza, Stephanie Lheureux, Neda Stjepanovic, Brendan Van As, Sarah Boross-Harmer, Lisa Wang, Trevor J Pugh, Pamela S Ohashi, Lillian L Siu, Daniel D De Carvalho
• Original research: Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma (30 July, 2020)

  Sara Bedrose, Kevin Charles Miller, Lina Altameemi, Mohamed S Ali, Sameh Nassar, Naveen Garg, Marilyne Daher, Keith D Eaton, Jeffrey Thomas Yorio, Davey B Daniel, Matthew Campbell, Keith C Bible, Mabel Ryder, Ashish V Chintakuntlawar, Mouhammed Amir Habra
• Original research: Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141⁺ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8⁺ T cells (30 July, 2020)

  Kelly-Anne Masterman, Oscar L Haigh, Kirsteen M Tullett, Ingrid M Leal-Rojas, Carina Walpole, Frances E Pearson, Jonathon Cebon, Christopher Schmidt, Liam O'Brien, Nikita Rosendahl, Ghazal Daraj, Irina Caminschi, Eric H Gschweng, Roger P Hollis, Donald B Kohn, Mireille H Lahoud, Kristen J Radford
• Original research: Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer (29 July, 2020)

  Kyoung-Ho Pyo, Sun Min Lim, Chae-Won Park, Ha-Ni Jo, Jae Hwan Kim, Mi-Ran Yun, Dohee Kim, Chun-Feng Xin, Wongeun Lee, Bianca Gheorghiu, Min Hee Hong, Hye Ryun Kim, Hyo Sup Shim, Mi Jang, Sung Sook Lee, Byoung Chul Cho
• Original research: Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses (23 July, 2020)

  Erika J Lampert, Ashley Cimino-Mathews, Joo Sang Lee, Jayakumar Nair, Min-Jung Lee, Akira Yuno, Daniel An, Jane B Trepel, Eytan Ruppin, Jung-Min Lee
• Original research: Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study (22 July, 2020)

  Chiun-Sheng Huang, Alice L Yu, Ling-Ming Tseng, Louis W C Chow, Ming-Feng Hou, Sara A Hurvitz, Richard B Schwab, James L Murray, Hsien-Kun Chang, Hong-Tai Chang, Shin-Cheh Chen, Sung-Bae Kim, Jung-Tung Hung, Shir-Hwa Ueng, Su-Hua Lee, Chwen-Cheng Chen, Hope S Rugo
• Original research: Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model (20 July, 2020)

  Sai Ping Lau, Nadine van Montfoort, Priscilla Kinderman, Melanie Lukkes, Larissa Klaase, Menno van Nimwegen, Mandy van Gulijk, Jasper Dumas, Dana A M Mustafa, Sanne L A Lievense, Christianne Groeneveldt, Ralph Stadhouders, Yunlei Li, Andrew Stubbs, Koen A Marijt, Heleen Vroman, Sjoerd H van der Burg, Joachim Aerts, Thorbald van Hall, Floris Dammeijer, Casper H J van Eijck
• Original research: In situ vaccination at a peripheral tumor site augments response against melanoma brain metastases (19 July, 2020)

  Paul A Clark, Raghava N Sriramaneni, Won Jong Jin, Justin C Jagodinsky, Amber M Bates, Abigail A Jaquish, Bryce R Anderson, Trang Le, Jonathan A Lubin, Ishan Chakravarty, Ian S Arthur, Clinton M Heinze, Emily I Guy, Jasdeep Kler, Kelsey A Klar, Peter M Carlson, Kyung Mann Kim, John S Kuo, Zachary S Morris
• Original research: Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy (19 July, 2020)

  Sjoerd T T Schetters, Ernesto Rodriguez, Laura J W Kruijssen, Matheus H W Crommentuijn, Louis Boon, Jan Van den Bossche, Joke M M Den Haan, Yvette Van Kooyk
• Original research: ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19 (15 July, 2020)

  Riyue Bao, Kyle Hernandez, Lei Huang, Jason John Luke
• Original research: Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial (12 July, 2020)

  Robert J Motzer, Bernard Escudier, David F McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Thomas Powles, Frede Donskov, Elizabeth R Plimack, Philippe Barthélémy, Hans J Hammers, Saby George, Viktor Grünwald, Camillo Porta, Victoria Neiman, Alain Ravaud, Toni K Choueiri, Brian I Rini, Pamela Salman, Christian K Kollmannsberger, Scott S Tykodi, Marc-Oliver Grimm, Howard Gurney, Raya Leibowitz-Amit, Poul F Geertsen, Asim Amin, Yoshihiko Tomita, M Brent McHenry, Shruti Shally Saggi, Nizar M Tannir
• Original research: Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort (7 July, 2020)

  Byoung Chul Cho, Amaury Daste, Alain Ravaud, Sébastien Salas, Nicolas Isambert, Edward McClay, Ahmad Awada, Christian Borel, Laureen S Ojalvo, Christoph Helwig, P Alexander Rolfe, James L Gulley, Nicolas Penel
• Original research: Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma (7 July, 2020)

  Jean Hoffman-Censits, Sumanta Pal, Constanze Kaiser, Beiying Ding, Joaquim Bellmunt
• Original research: Phase I study of the ¹⁷⁷Lu-DOTA⁰-Tyr³-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung (2 July, 2020)

  Chul Kim, Stephen V Liu, Deepa S Subramaniam, Tisdrey Torres, Massimo Loda, Giuseppe Esposito, Giuseppe Giaccone
• Original research: A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone (2 July, 2020)

  Julie N Graff, Tomasz M Beer, Joshi J Alumkal, Rachel E Slottke, William L Redmond, George V Thomas, Reid F Thompson, Mary A Wood, Yoshinobu Koguchi, Yiyi Chen, Emile Latour, Raymond C Bergan, Charles G Drake, Amy E Moran
• Original research: Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer (2 July, 2020)

  Marta Trüb, Franziska Uhlenbrock, Christina Claus, Petra Herzig, Martin Thelen, Vaios Karanikas, Marina Bacac, Maria Amann, Rosemarie Albrecht, Claudia Ferrara-Koller, Daniela Thommen, Sacha Rothschield, Spasenija Savic Prince, Kirsten D Mertz, Gieri Cathomas, Robert Rosenberg, Viola Heinzelmann-Schwarz, Mark Wiese, Didier Lardinois, Pablo Umana, Christian Klein, Heinz Laubli, Abhishek S Kashyap, Alfred Zippelius
• Original research: Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study (30 June, 2020)

  Tomoko Kobayashi, Shintaro Iwama, Yoshinori Yasuda, Norio Okada, Takayuki Okuji, Masaaki Ito, Takeshi Onoue, Motomitsu Goto, Mariko Sugiyama, Taku Tsunekawa, Hiroshi Takagi, Daisuke Hagiwara, Yoshihiro Ito, Hidetaka Suga, Ryoichi Banno, Kenji Yokota, Tetsunari Hase, Masahiro Morise, Naozumi Hashimoto, Masahiko Ando, Yasushi Fujimoto, Hideharu Hibi, Michihiko Sone, Yuichi Ando, Masashi Akiyama, Yoshinori Hasegawa, Hiroshi Arima